Predicted protein targets (top 5)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PIK3CD | O00329 | 17/20 | 0.58 |
| ▸ | PIK3CB | P42338 | 17/20 | 0.58 |
| ▸ | PIK3CA | P42336 | 15/20 | 0.56 |
| ▸ | PRKDC | P78527 | 2/20 | 0.53 |
| ▸ | MTOR | P42345 | 1/20 | 0.53 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3721705 | 0.84 | PIK3CD (0.42) | PIK3CDPIK3CBPIK3CA | |
| SCHEMBL3718193 | 0.84 | PIK3CD (0.42) | PIK3CDPIK3CBPIK3CA | |
| SCHEMBL3714687 | 0.83 | PRKDC (0.41) | PIK3CDPIK3CBPIK3CAPRKDC | |
| SCHEMBL13752195 | 0.81 | PIK3CD (0.69) | PIK3CDPIK3CBPIK3CAPRKDCMTOR | |
| SCHEMBL13752191 | 0.78 | PIK3CB (0.68) | PIK3CDPIK3CBPIK3CAPRKDCMTOR | |
| SCHEMBL13403480 | 0.77 | PRKDC (0.64) | PIK3CDPIK3CBPIK3CAPRKDCMTOR | |
| SCHEMBL3718056 | 0.77 | PRKDC (0.71) | PIK3CDPIK3CBPIK3CAPRKDCMTOR | |
| SCHEMBL8160997 | 0.75 | PRKDC (0.64) | PIK3CDPIK3CBPIK3CAPRKDCMTOR | |
| SCHEMBL13752231 | 0.75 | PIK3CD (0.69) | PIK3CDPIK3CBPIK3CAPRKDCMTOR | |
| SCHEMBL13403441 | 0.75 | LMNA (0.37) | PIK3CDPIK3CBPIK3CAPRKDC |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2010136778-A1 | DIBENZOTHIOPHENE DERIVATIVES AS DNA- PK INHIBITORS | KUDOS PHARMACEUTICALS LIMITED (GB) | 2010-12-02 | — | — | WO | disclosed |
| WO-2010136778-A1 | DIBENZOTHIOPHENE DERIVATIVES AS DNA- PK INHIBITORS | KUDOS PHARMACEUTICALS LIMITED (GB) | 2010-12-02 | — | — | WO | disclosed |
| US-7696203-B2 | DNA-PK inhibitors | KUDOS PHARMACEUTICALS LIMITED (GB) | 2010-04-13 | — | — | US | disclosed |
| US-7696203-B2 | DNA-PK inhibitors | KUDOS PHARMACEUTICALS LIMITED (GB) | 2010-04-13 | — | — | US | disclosed |
| US-7696203-B2 | DNA-PK inhibitors | KUDOS PHARMACEUTICALS LIMITED (GB) | 2010-04-13 | — | — | US | disclosed |
| US-20060264427-A1 | 3-amino-N-[4-(2-morpholin-4-yl-1-benzopyran-4-one)-dibenzofuran-1-yl]-propionamides ; anticancer, antitumor agents | KUDOS PHARMACEUTICALS LIMITED (GB) | 2006-11-23 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060264427-A1 | 3-amino-N-[4-(2-morpholin-4-yl-1-benzopyran-4-one)-dibenzofuran-1-yl]-propionamides ; anticancer, antitumor agents | POLK, DCK, POLN | PIK3CD 1459/4885PIK3CB 1519/4885PIK3CA 1723/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.